IFL is developing a portfolio of biomaterial platforms with broad potential across immunology and therapeutic delivery that have proven efficacy in multiple pre-clinical models of disease. Current areas of focus include
- Manganese-based inorganic gels as adjuvants for livestock vaccines
- B cell-targeting microparticles for autoimmune disease treatment
- Solid emulsion systems for sustained biologic release
- Metal-organic frameworks for vaccine thermostability
These technologies are being developed to address unmet needs in immune modulation, stability, delivery, and efficacy.